PLIANT THERAPEUTICS, INC. Payments to Acquire Short-term Investments
PLIANT THERAPEUTICS, INC. (PLRX) reported Payments to Acquire Short-term Investments of $82.22 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2026-08-11
- PLIANT THERAPEUTICS, INC. payments to acquire short-term investments for the quarter ending 2026-06-30 was $17.32M, a 66.45% decline year-over-year.
- PLIANT THERAPEUTICS, INC. payments to acquire short-term investments for the quarter ending 2026-03-31 was $64.90M, a 358.69% increase year-over-year.
- PLIANT THERAPEUTICS, INC. payments to acquire short-term investments for the quarter ending 2025-12-31 was $85.08M, a 155.09% increase year-over-year.
- PLIANT THERAPEUTICS, INC. payments to acquire short-term investments for the quarter ending 2025-09-30 was $52.56M, a 31.77% decline year-over-year.
- PLIANT THERAPEUTICS, INC. payments to acquire short-term investments for fiscal 2025 was $203.40M, a 3.73% decline from fiscal 2024.
- PLIANT THERAPEUTICS, INC. payments to acquire short-term investments for fiscal 2024 was $211.28M, a 63.76% decline from fiscal 2023.
- PLIANT THERAPEUTICS, INC. payments to acquire short-term investments for fiscal 2023 was $583.07M, a 79.01% increase from fiscal 2022.
- PLIANT THERAPEUTICS, INC. payments to acquire short-term investments for fiscal 2022 was $325.72M, a 48.13% increase from fiscal 2021.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $17.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $82.22M 10-Q · filed 2026-08-11 | $167.30M derived: sum of 3 quarters · filed 2026-08-11 | $219.86M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $64.90M 10-Q · filed 2026-05-11 | $149.99M derived: sum of 2 quarters · filed 2026-05-11 | $202.55M derived: sum of 3 quarters · filed 2026-05-11 | $254.16M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $85.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $137.65M derived: sum of 2 quarters · filed 2026-03-11 | $189.25M derived: sum of 3 quarters · filed 2026-08-11 | $203.40M 10-K · filed 2026-03-11 |
| 2025-09-30 | $52.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $104.17M derived: sum of 2 quarters · filed 2026-08-11 | $118.32M 10-Q · filed 2025-11-06 | $151.67M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $51.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $65.76M 10-Q · filed 2026-08-11 | $99.11M derived: sum of 3 quarters · filed 2026-08-11 | $176.14M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $14.15M 10-Q · filed 2026-05-11 | $47.50M derived: sum of 2 quarters · filed 2026-05-11 | $124.54M derived: sum of 3 quarters · filed 2026-05-11 | $173.06M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $33.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $110.39M derived: sum of 2 quarters · filed 2026-03-11 | $158.91M derived: sum of 3 quarters · filed 2026-03-11 | $211.28M 10-K · filed 2026-03-11 |
| 2024-09-30 | $77.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $125.56M derived: sum of 2 quarters · filed 2025-11-06 | $177.93M 10-Q · filed 2025-11-06 | $235.43M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $48.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $100.90M 10-Q · filed 2025-08-07 | $158.39M derived: sum of 3 quarters · filed 2025-08-07 | $272.87M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $52.38M 10-Q · filed 2025-05-08 | $109.87M derived: sum of 2 quarters · filed 2025-05-08 | $224.35M derived: sum of 3 quarters · filed 2025-05-08 | $358.82M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $57.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $171.97M derived: sum of 2 quarters · filed 2025-03-03 | $306.45M derived: sum of 3 quarters · filed 2025-03-03 | $583.07M 10-K · filed 2025-03-03 |
| 2023-09-30 | $114.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $248.95M derived: sum of 2 quarters · filed 2024-11-07 | $525.57M 10-Q · filed 2024-11-07 | $561.89M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $134.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $411.10M 10-Q · filed 2024-08-07 | $447.41M derived: sum of 3 quarters · filed 2025-03-03 | $658.76M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $276.62M 10-Q · filed 2024-05-06 | $312.93M derived: sum of 2 quarters · filed 2025-03-03 | $524.29M derived: sum of 3 quarters · filed 2025-03-03 | $563.11M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $36.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $247.67M derived: sum of 2 quarters · filed 2025-03-03 | $286.49M derived: sum of 3 quarters · filed 2025-03-03 | $325.72M 10-K · filed 2025-03-03 |
| 2022-09-30 | $211.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $250.17M derived: sum of 2 quarters · filed 2023-11-09 | $289.40M 10-Q · filed 2023-11-09 | $327.32M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $38.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $78.05M 10-Q · filed 2023-08-09 | $115.97M derived: sum of 3 quarters · filed 2024-02-27 | $159.10M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $39.23M 10-Q · filed 2023-05-09 | $77.15M derived: sum of 2 quarters · filed 2024-02-27 | $120.28M derived: sum of 3 quarters · filed 2024-02-27 | $194.31M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $37.92M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $81.06M derived: sum of 2 quarters · filed 2024-02-27 | $155.08M derived: sum of 3 quarters · filed 2024-02-27 | $219.89M 10-K · filed 2024-02-27 |
| 2021-09-30 | $43.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $117.16M derived: sum of 2 quarters · filed 2022-11-08 | $181.97M 10-Q · filed 2022-11-08 | $236.75M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $74.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $138.83M 10-Q · filed 2022-08-08 | $193.62M derived: sum of 3 quarters · filed 2022-08-08 | $320.40M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $64.81M 10-Q · filed 2022-05-09 | $119.59M derived: sum of 2 quarters · filed 2022-05-09 | $246.38M derived: sum of 3 quarters · filed 2022-05-09 | $376.40M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $54.79M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $181.57M derived: sum of 2 quarters · filed 2022-03-01 | $311.60M derived: sum of 3 quarters · filed 2022-03-01 | $322.61M 10-K · filed 2022-03-01 |
| 2020-09-30 | $126.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $256.81M derived: sum of 2 quarters · filed 2021-11-09 | $267.82M 10-Q · filed 2021-11-09 | $284.78M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $130.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $141.03M 10-Q · filed 2021-08-09 | $158.00M derived: sum of 3 quarters · filed 2022-03-01 | $159.99M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $11.01M 10-Q · filed 2021-05-10 | $27.97M derived: sum of 2 quarters · filed 2022-03-01 | $29.96M derived: sum of 3 quarters · filed 2022-03-01 | |
| 2019-12-31 | $16.96M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $18.95M derived: sum of 2 quarters · filed 2022-03-01 | $51.71M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $1.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $34.75M 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $32.76M 10-Q · filed 2020-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |